Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
29.43
0.00 (0.00%)
Aug 24, 2026, 9:32 AM EDT - Market open
Maze Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 202.64 | 189.25 | 196.81 | 29.16 | 99.92 |
Short-Term Investments | 208.44 | 152.67 | - | - | - |
Cash & Short-Term Investments | 411.09 | 341.92 | 196.81 | 29.16 | 99.92 |
Cash Growth | 55.40% | 73.73% | 574.99% | -70.82% | - |
Other Receivables | 2.8 | 1.5 | - | - | - |
Receivables | 2.8 | 1.5 | - | - | - |
Prepaid Expenses | 6.54 | 6.3 | 4.86 | 4.95 | 6.23 |
Total Current Assets | 420.42 | 349.72 | 201.67 | 34.11 | 106.15 |
Property, Plant & Equipment | 22.83 | 25.16 | 29.92 | 34.98 | 41.23 |
Long-Term Investments | 83.82 | 18.11 | - | - | - |
Long-Term Deferred Charges | - | - | 4.6 | - | - |
Other Long-Term Assets | 4.55 | 4.14 | 4.35 | 2.41 | 2.58 |
Total Assets | 531.63 | 397.13 | 240.54 | 71.5 | 149.96 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 2.21 | 1.79 | 1.94 | 2.02 | 1.59 |
Accrued Expenses | 15.87 | 15.97 | 14.1 | 9.81 | 14.87 |
Current Portion of Leases | 4.88 | 4.8 | 4.63 | 4.49 | 4.32 |
Total Current Liabilities | 22.96 | 22.56 | 20.67 | 16.32 | 20.78 |
Long-Term Debt | 38.96 | - | - | 20.08 | - |
Long-Term Leases | 16.58 | 18.51 | 22 | 25.05 | 27.73 |
Other Long-Term Liabilities | - | 1.09 | 0.97 | - | - |
Total Liabilities | 78.5 | 42.16 | 43.64 | 61.45 | 48.51 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0.06 | 0.05 | 0 | 0 | 0.02 |
Additional Paid-In Capital | 1,012 | 844.35 | 47.24 | 21.84 | 12.79 |
Retained Earnings | -558.48 | -489.55 | -358.43 | -395.69 | -295.27 |
Comprehensive Income & Other | -0.44 | 0.11 | - | - | - |
Total Common Equity | 453.12 | 354.97 | -311.18 | -373.85 | -282.46 |
Shareholders' Equity | 453.12 | 354.97 | 196.9 | 10.05 | 101.44 |
Total Liabilities & Equity | 531.63 | 397.13 | 240.54 | 71.5 | 149.96 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 60.42 | 23.31 | 26.63 | 49.62 | 32.06 |
Net Cash (Debt) | 434.49 | 318.61 | 170.18 | -20.47 | 67.86 |
Net Cash Growth | 81.39% | 87.22% | - | - | - |
Net Cash Per Share | 8.19 | 7.41 | 62.33 | -8.94 | 33.76 |
Filing Date Shares Outstanding | 55.55 | 49.71 | 43.8 | 2.32 | 2.01 |
Total Common Shares Outstanding | 55.5 | 49.33 | 2.44 | 2.32 | 2.01 |
Working Capital | 397.46 | 327.16 | 181 | 17.79 | 85.37 |
Book Value Per Share | 8.16 | 7.20 | -127.72 | -160.95 | -140.52 |
Tangible Book Value | 453.12 | 354.97 | -311.18 | -373.85 | -282.46 |
Tangible Book Value Per Share | 8.16 | 7.20 | -127.72 | -160.95 | -140.52 |
Machinery | - | 17.97 | 17.31 | 16.47 | 16.08 |
Construction In Progress | - | 0.04 | 0.03 | 0.06 | - |
Leasehold Improvements | - | 5.51 | 5.45 | 5.36 | 5.33 |